Applied DNA Sciences Begins a Testing Program for Novel Anti-Sepsis Agents for Accuthera, Inc.

Jul 27, 2006, 01:00 ET from Applied DNA Sciences, Inc.

    STONY BROOK, N.Y., July 27 /PRNewswire-FirstCall/ -- Applied DNA
 Sciences, Inc. (OTC Bulletin Board:   APDN), a DNA security solutions
 company, today announced that it has agreed to a commercial agreement
 providing for APDN to manage a portion of a testing program for Accuthera,
 Inc, focusing on evaluation of a novel series of proteinase inhibitors. The
 Accuthera program is being conducted in conjunction with an ongoing major
 initiative of the Rocky Mountain Regional Center of Excellence in Fort
 Collins, CO, under the sponsorship of the National Institute of Allergy and
 Infectious Diseases.
     Accuthera is pursuing the development of a novel series of low
 molecular weight compounds for controlling the systemic inflammation
 associated with sepsis. This condition is associated with high morbidity
 and mortality. Previous efforts to develop successful targeted therapeutic
 strategies for sepsis have been limited by incomplete understanding of the
 requirements for optimal drug design as well as inadequate detection of
 early warning signs of escalating systemic inflammatory responses in septic
 patients. If these warning signs could be recognized with greater
 reliability, the effectiveness of therapeutic interventions could be
 considerably increased. Accuthera's approach makes use of rigorous
 evaluation of biomarkers under conditions amenable to monitoring in the
 hospital bedside setting as well as comprehensive evaluation of the
 functional efficacy of its candidate proteinase inhibitors under conditions
 replicating the onset of the systemic inflammatory response.
     Dr. John C. Cheronis, M.D., Ph.D, CEO of Accuthera Inc., stated, "We
 are very pleased to develop a collaboration with Applied DNA Sciences. The
 results from the tests to be funded by us and managed by Applied DNA will
 help us screen candidate drugs for efficacy using a number of in vitro
     Dr. James A. Hayward, Ph.D., Sc.D., CEO of APDN, stated, "The current
 management team at Applied has extensive previous experience with the
 development and commercialization of proteinase inhibitors. In addition,
 our decision to join this partnership is to also designed to facilitate
 collaboration between Accuthera and investigators at Stony Brook
 University. APDN is seeking to increase its presence in the pharma and
 biotech industries, where the scientific foundations of APDN's platforms
 can be applied to prevent the production and distribution of counterfeit
     About Applied DNA Sciences, Inc.
     Applied DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded
 security solutions that use plant DNA to verify authenticity and protect
 corporate and government agencies from counterfeiting, fraud, piracy,
 product diversion, identity theft and unauthorized intrusion into physical
 plant and databases. Our common stock is registered under Section 12(g) of
 the Securities Exchange Act of 1934 and is listed on the Over-The-Counter
 Bulletin Board under the symbol "APDN". Contact: MeiLin Wan, Applied DNA
 Sciences, Inc., 25 Health Sciences Drive, Stony Brook, New York 11790; Tel:
 631-444-6370; Fax: 631-444.8848
     The statements made by Applied DNA Sciences, Inc. may be
 forward-looking in nature and are made pursuant to the safe harbor
 provisions of the Private Securities Litigation Reform Act of 1995.
 Forward-looking statements describe the Company's future plans,
 projections, strategies and expectations, and are based on assumptions and
 involve a number of risks and uncertainties, many of which are beyond the
 control of Applied DNA Sciences, Inc. Actual results could differ
 materially from those projected due to changes in interest rates, market
 competition, changes in the local and national economies, and various other
 factors detailed from time to time in Applied DNA Sciences' SEC reports and
 filings, including our Annual Report on Form 10-KSB, filed on January 12,
 2006, our subsequent Quarterly Reports on Form 10-QSB, and our Current
 Reports on Form 8-K. The Company undertakes no obligation to update
 publicly any forward-looking statements to reflect new information, events
 or circumstances after the date hereof to reflect the occurrence of
 unanticipated events.

SOURCE Applied DNA Sciences, Inc.